EXtension of Tablo TrEatmeNt Duration Registry

NCT04912050 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33

Last updated 2022-08-12

No results posted yet for this study

Summary

Observational, retrospective and prospective, multicenter, post-market study of the Tablo Hemodialysis System in hospitalized participants with End-Stage Kidney Disease or Acute Kidney Injury who are prescribed renal replacement therapy \> 12 hours.

Conditions

Interventions

DEVICE

Tablo Hemodialysis System

Renal Replacement Therapy between 12\< to ≤ 24 hours.

Sponsors & Collaborators

  • Outset Medical

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-25
Primary Completion
2022-05-31
Completion
2022-05-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04912050 on ClinicalTrials.gov